Annals of the American Thoracic Society

Journal

Publication Venue For

  • avorable Clinician Acceptability of Telehealth as Part of the Cystic Fibrosis Care Model during the COVID-19 Pandemic.  18:1588-1592. 2021
  • Video Telehealth Pulmonary Rehabilitation for COPD is Associated with Clinical Improvement Similar to Center Based Pulmonary Rehabilitation. 2021
  • Portable, consumer-grade pulse oximeters are accurate for home and medical use: Implications for their use in patients with COVID-19.  18:1260-1261. 2021
  • The long and the short of it: Is "long covid" more than slow resolution of the acute disease?.  18:948-950. 2021
  • Risk of exacerbation and pneumonia with single-inhaler triple versus dual therapy in IMPACT.  18:788-798. 2021
  • The ARREST Pneumonia clinical trial: Rationale and design.  18:698-708. 2021
  • Chronotropic Index and Acute Exacerbations of COPD: A Secondary Analysis of BLOCK COPD. 2021
  • Niranjan SJ, Opoku-Agyeman W, Carroll NW, Dorsey A, Tipre M, Baskin ML, Dransfield MT. Distribution and Geographic Accessibility of Lung Cancer Screening Centers in the US. Ann Am Thorac Soc. 2021 Mar 30. doi: 10.1513/AnnalsATS.202010-1313RL. Epub ahead of print. PMID: 33784236. 2021
  • Defining Resilience to Smoking Related Lung Disease: A Modified Delphi Approach from SPIROMICS. 2021
  • Social inequities and cystic fibrosis outcomes: we can do better.  18:215-217. 2021
  • Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR A Clinical Trial.  18:75-83. 2021
  • Recipient Age Impacts Long-Term Survival in Adult Subjects with Cystic Fibrosis after Lung Transplantation.  18:44-50. 2021
  • The pulmonary fibrosis foundation patient registry: Rationale, design, and methods.  17:1620-1628. 2020
  • Upper airway stimulation versus untreated comparators in positive airway pressure treatment-refractory obstructive sleep apnea.  17:1610-1619. 2020
  • Risk Factors for Cardiovascular Collapse during Tracheal Intubation of Critically III Adults.  17:1021-1024. 2020
  • Both Duration and Pack-Years of Tobacco Smoking Should Be Used for Clinical Practice and Research.  17:804-806. 2020
  • Effect of zephyr endobronchial valves on dyspnea, activity levels, and quality of life at one year: Results from a randomized clinical trial.  17:829-838. 2020
  • Associations between patient-reported outcomes and death or lung transplant in idiopathic pulmonary fibrosis data from the idiopathic pulmonary fibrosis prospective outcomes registry.  17:699-705. 2020
  • Changes in airway microbiome and inflammation with ivacaftor treatment in patients with cystic fibrosis and the G551D mutation.  17:212-220. 2020
  • A formative evaluation of patient and family caregiver perspectives on early palliative care in chronic obstructive pulmonary disease across disease severity.  16:1024-1033. 2019
  • Emulating a novel clinical trial using existing observational data predicting results of the PREVENT study.  16:998-1007. 2019
  • Imaging small airway disease: Probabilities and possibilities.  16:975-977. 2019
  • The peak index: Spirometry metric for airflow obstruction severity and heterogeneity.  16:982-989. 2019
  • Physical function trajectories in survivors of acute respiratory failure.  16:471-477. 2019
  • Safety and tolerability of comprehensive research bronchoscopy in chronic obstructive pulmonary disease results from the SPIROMICS bronchoscopy substudy.  16:439-446. 2019
  • Alignment of inhaled chronic obstructive pulmonary disease therapies with published strategies :analysis of the Global Initiative for Chronic Obstructive Lung Disease recommendations in SpiroMics.  16:200-208. 2019
  • Reducing chronic obstructive pulmonary disease hospital readmissions: An official American Thoracic Society workshop report.  16:161-170. 2019
  • Acquired cystic fibrosis transmembrane conductance regulator dysfunction and radiographic bronchiectasis in current and former smokers: A cross-sectional study.  16:150-153. 2019
  • Combined forced expiratory volume in 1 second and forced vital capacity bronchodilator response, exacerbations, and mortality in chronic obstructive pulmonary disease.  16:826-835. 2019
  • How to detect tobacco-related vasculopathy: Are we there yet?.  16:674-675. 2019
  • It’s time to rehabilitate pulmonary rehabilitation.  16:55-57. 2019
  • Occupational exposures and computed tomographic imaging characteristics in the SpiromICS cohort.  15:1411-1419. 2018
  • Functional anatomic imaging of the airway surface.  15:S177-S183. 2018
  • Risk factors for and prediction of hypoxemia during tracheal intubation of Critically Ill Adults.  15:1320-1327. 2018
  • Searching for the source of the leak: PIE and the macklin effect.  15:1354-1356. 2018
  • Rural residence and chronic obstructive pulmonary disease exacerbations: Analysis of the SPIROMICS cohort.  15:808-815. 2018
  • Anemia and Adverse Outcomes in a Chronic Obstructive Pulmonary Disease Population with a High Burden of Comorbidities. An Analysis from SPIROMICS..  15:710-717. 2018
  • B-blocker therapy and clinical outcomes in patients with moderate chronic obstructive pulmonary disease and heightened cardiovascular risk an observational substudy of SUMMIT.  15:608-614. 2018
  • Home-based physical activity coaching, physical activity, and health care utilization in chronic obstructive pulmonary disease chronic obstructive pulmonary disease self-management activation research trial secondary outcomes.  15:470-478. 2018
  • Paratracheal paraseptal emphysema and expiratory central airway collapse in smokers.  15:479-484. 2018
  • Recent advances in computed tomography imaging in chronic obstructive pulmonary disease.  15:281-289. 2018
  • Diagnosis of chronic obstructive pulmonary disease: Breathing new life into an old debate.  15:163-165. 2018
  • Reply: We did this, and the patient improved: True, true, and unrelated?.  15:269. 2018
  • The "Obesity paradox" in chronic obstructive pulmonary disease: Can it be resolved?.  15:158-159. 2018
  • The long-term oxygen treatment trial for chronic obstructive pulmonary disease: Rationale, design, and lessons learned.  15:89-101. 2018
  • Handgrip strength in chronic obstructive pulmonary disease associations with acute exacerbations and body composition.  14:1638-1645. 2017
  • Mitochondrial dysfunction in pulmonary fibrosis.  14:S383-S388. 2017
  • Progressive dyspnea and back pain after complicated pneumonia.  14:1714-1717. 2017
  • Clinical risk factors and prognostic model for primary graft dysfunction after lung transplantation in patients with pulmonary hypertension.  14:1514-1522. 2017
  • Going with the flow: Saddle pulmonary embolism complicated by severe hypoxemia without shock.  14:1479-1484. 2017
  • Measures of frailty in chronic lung diseases.  14:1266-1267. 2017
  • An official American Thoracic Society Workshop Report: Chemical inhalational disasters biology of lung injury, development of novel therapeutics, and medical preparedness.  14:1060-1072. 2017
  • Respiratory symptoms items from the COPD assessment test identify ever-smokers with preserved lung function at higher risk for poor respiratory outcomes an analysis of the subpopulations and intermediate outcome measures in COPD Study cohort.  14:636-642. 2017
  • Results of a Medicare Bundled Payments for care Improvement initiative for chronic obstructive pulmonary disease readmissions.  14:643-648. 2017
  • Abnormal glucose metabolism and high-energy expenditure in idiopathic pulmonary arterial hypertension.  14:190-199. 2017
  • Characterization of prostacyclin-associated leg pain in patients with pulmonary arterial hypertension.  14:206-212. 2017
  • Lumacaftor/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTR.  14:213-219. 2017
  • Pulmonary rehabilitation improves outcomes in chronic obstructive pulmonary disease independent of disease burden.  14:26-32. 2017
  • Constrictive bronchiolitis in cystic fibrosis adolescents with refractory pulmonary decline.  13:2174-2183. 2016
  • Persistent and newly developed chronic bronchitis are associated with worse outcomes in chronic obstructive pulmonary disease.  13:1016-1025. 2016
  • A lifestyle physical activity intervention for patients with chronic obstructive pulmonary disease a randomized controlled trial.  13:617-626. 2016
  • Vitamin D concentrations and obstructive sleep apnea in a multicenter cohort of older males.  13:712-718. 2016
  • Neutrophil fates in bronchiectasis and alpha-1 antitrypsin deficiency.  13:S123-S129. 2016
  • Therapeutic approaches to acquired cystic fibrosis transmembrane conductance regulator dysfunction in Chronic bronchitis.  13:S169-S176. 2016
  • Depression is associated with readmission for acute exacerbation of chronic obstructive pulmonary disease.  13:197-203. 2016
  • Increased costs of the asthma-chronic obstructive pulmonary disease overlap syndrome one syndrome for the price of two?.  13:158-159. 2016
  • Attenuation of MIR-17∼92 cluster in bronchopulmonary dysplasia.  12:1506-1513. 2015
  • Spontaneous hemothorax resulting from tissue plasminogen activator in a patient with ischemic stroke and unrecognized recent myocardial infarction.  12:1105-1106. 2015
  • Reduced bone density and vertebral fractures in smokers. Men and COPD patients at increased risk.  12:648-656. 2015
  • Multicenter observational study on factors and outcomes associated with various methicillin-resistant Staphylococcus aureus types in children with cystic fibrosis.  12:864-871. 2015
  • Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD.  12:27-34. 2015
  • Characteristics of patients with pulmonary venoocclusive disease awaiting transplantation.  11:1411-1418. 2014
  • Pneumothorax risk factors in smokers with and without chronic obstructive pulmonary disease.  11:1387-1394. 2014
  • The feasibility of lung transplantation in HIV-seropositive patients.  11:945-950. 2014
  • Domain-specific self-efficacy is associated with measures of functional capacity and quality of life among patients with moderate to severe chronic obstructive pulmonary disease.  11:310-315. 2014
  • FEV1/FEV6to diagnose airflow obstruction: Comparisons with computed tomography and morbidity indices.  11:335-341. 2014
  • Predictors of early readmission among patients 40 to 64 years of age hospitalized for chronic obstructive pulmonary disease.  11:685-694. 2014
  • Quantitative computed tomography measures of pectoralis muscle area and disease severity in chronic obstructive pulmonary disease: A cross-sectional study.  11:326-334. 2014
  • Adult-onset asthma becomes the dominant phenotype among women by age 40 years: The longitudinal CARDIA study.  10:188-197. 2013
  • Exposing animals to oxidant gases: Nose only vs. whole body.  7:264-268. 2010
  • Mechanisms and modification of chlorine-induced lung injury in animals.  7:278-283. 2010
  • Potential for chlorine gas-induced injury in the extrapulmonary vasculature.  7:290-293. 2010
  • Understanding and treating chlorine-induced lung injury.  7:253. 2010
  • An official American Thoracic Society Workshop Report: Tobacco control initiatives within the American Thoracic Society.  7:1-7. 2010
  • Pharmacologic therapy: Novel approaches for chronic obstructive pulmonary disease.  4:543-548. 2007
  • Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials.  4:387-398. 2007
  • Altered T-cell phenotypes in chronic obstructive pulmonary disease.  3:487-488. 2006
  • Regulation of Na+ channels in lung alveolar type II epithelial cells..  1:10-16. 2004
  • International Standard Serial Number (issn)

  • 1546-3222
  • 2325-6621
  • 2329-6933
  • Electronic International Standard Serial Number (eissn)

  • 1546-3222
  • 1943-5665
  • 2325-6621